To make autologous cellular immunotherapy a reality, Dendreon has developed a unique manufacturing process. Discover how it works in this video.
PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. PROVENGE is designed to induce an immune response against prostate cancer. To learn more, please visit provenge.com.
We are also currently evaluating a variety of therapeutic approaches that share a common attribute: a targeted therapy platform that provides patients with new treatment options and may improve the lives of patients. For the latest news, please visit dendreon.com.